FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387666168> ?p ?o ?g. }

• W4387666168 endingPage "e0290644" @default.
• W4387666168 startingPage "e0290644" @default.
• W4387666168 abstract "The triple combination of hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitors (ICIs) is expected to have a synergistic anticancer effect in HCC. We conducted this meta-analysis to evaluate the efficacy and safety of the triple combination treatment in advanced HCC patients.PubMed, Embase, Cochrane Library, Web of Science databases were systematically searched for relevant studies from the inception of each database to May 10, 2023. All articles focusing the triple combination treatment of HAIC-FO plus TKI and ICIs for advanced HCC were eligible. The meta-analysis was conducted following the PRISMA guidelines. The risk of bias was assessed using the Joanna Briggs Institute (JBI) for case series and Newcastle-Ottawa Scale (NOS) for cohort studies. The primary outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR). The secondary results were adverse events. Further meta-analysis of control studies demonstrated the superiority of the triple combination modality to TKI plus ICIs, and TKI alone.Nine articles (four cohort studies and five one-arm studies) involving 777 advanced HCC patients were included in this meta-analysis. In terms of survival analysis, the pooled median PFS was 11 months (95% CI: 10.1-12.0 months) with low heterogeneity (I2 = 0%, p = 0.97). With regard to tumor response, the pooled ORR and DCR was 61.6% (I2=0%, p = 0.71) and 87.9% (I2 = 13%, p = 0.33) with low heterogeneity, respectively. As compared with TKIs plus ICIs, and TKIs alone, the triple combination thrapy was associated with improved median OS (HR=0.51, 95%CI 0.41-0.62) with low heterogeneity across studies (I2 = 0%, p = 0.47), median PFS (HR=0.51, 95%CI 0.41-0.64) with low heterogeneity across studies (I2 = 0%, p = 0.41), ORR (RR = 0.56, 95% CI: 0.42-0.74) with high heterogeneity across studies (I2 = 69%, p = 0.02), and DCR (RR = 0.38, 95%CI 0.27-0.54) with low heterogeneity across studies (I2 = 14%, p = 0.32). The most common 3/4 AEs were elevated ALT and AST, thrombocytopenia, hypertension, nausea and vomiting in this meta-analysis.The triple combination therapy of HAIC-FO plus TKI and ICIs showed promising efficacy and safety in patients with advanced HCC.The protocol was registered with PROSPERO (ID:CRD42023424281)." @default.
• W4387666168 created "2023-10-17" @default.
• W4387666168 creator A5000940783 @default.
• W4387666168 creator A5012536710 @default.
• W4387666168 creator A5012944390 @default.
• W4387666168 creator A5018940792 @default.
• W4387666168 creator A5032346755 @default.
• W4387666168 creator A5036708235 @default.
• W4387666168 creator A5048535438 @default.
• W4387666168 creator A5059975182 @default.
• W4387666168 creator A5077384746 @default.
• W4387666168 creator A5080280424 @default.
• W4387666168 date "2023-10-16" @default.
• W4387666168 modified "2023-10-18" @default.
• W4387666168 title "Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis" @default.
• W4387666168 cites W2079586464 @default.
• W4387666168 cites W2727497670 @default.
• W4387666168 cites W3006617177 @default.
• W4387666168 cites W3025022288 @default.
• W4387666168 cites W3128646645 @default.
• W4387666168 cites W3134644767 @default.
• W4387666168 cites W3162270595 @default.
• W4387666168 cites W3166753505 @default.
• W4387666168 cites W3204245666 @default.
• W4387666168 cites W3205893412 @default.
• W4387666168 cites W3213277274 @default.
• W4387666168 cites W3214415684 @default.
• W4387666168 cites W4220929644 @default.
• W4387666168 cites W4224442586 @default.
• W4387666168 cites W4226253134 @default.
• W4387666168 cites W4289890836 @default.
• W4387666168 cites W4294344007 @default.
• W4387666168 cites W4297383945 @default.
• W4387666168 cites W4310569280 @default.
• W4387666168 cites W4311472996 @default.
• W4387666168 cites W4319335912 @default.
• W4387666168 cites W4323812364 @default.
• W4387666168 doi "https://doi.org/10.1371/journal.pone.0290644" @default.
• W4387666168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37844117" @default.
• W4387666168 hasPublicationYear "2023" @default.
• W4387666168 type Work @default.
• W4387666168 citedByCount "0" @default.
• W4387666168 crossrefType "journal-article" @default.
• W4387666168 hasAuthorship W4387666168A5000940783 @default.
• W4387666168 hasAuthorship W4387666168A5012536710 @default.
• W4387666168 hasAuthorship W4387666168A5012944390 @default.
• W4387666168 hasAuthorship W4387666168A5018940792 @default.
• W4387666168 hasAuthorship W4387666168A5032346755 @default.
• W4387666168 hasAuthorship W4387666168A5036708235 @default.
• W4387666168 hasAuthorship W4387666168A5048535438 @default.
• W4387666168 hasAuthorship W4387666168A5059975182 @default.
• W4387666168 hasAuthorship W4387666168A5077384746 @default.
• W4387666168 hasAuthorship W4387666168A5080280424 @default.
• W4387666168 hasBestOaLocation W43876661681 @default.
• W4387666168 hasConcept C121608353 @default.
• W4387666168 hasConcept C126322002 @default.
• W4387666168 hasConcept C143998085 @default.
• W4387666168 hasConcept C197934379 @default.
• W4387666168 hasConcept C2776478404 @default.
• W4387666168 hasConcept C2778019345 @default.
• W4387666168 hasConcept C2778260052 @default.
• W4387666168 hasConcept C2780962732 @default.
• W4387666168 hasConcept C526805850 @default.
• W4387666168 hasConcept C71924100 @default.
• W4387666168 hasConcept C95190672 @default.
• W4387666168 hasConceptScore W4387666168C121608353 @default.
• W4387666168 hasConceptScore W4387666168C126322002 @default.
• W4387666168 hasConceptScore W4387666168C143998085 @default.
• W4387666168 hasConceptScore W4387666168C197934379 @default.
• W4387666168 hasConceptScore W4387666168C2776478404 @default.
• W4387666168 hasConceptScore W4387666168C2778019345 @default.
• W4387666168 hasConceptScore W4387666168C2778260052 @default.
• W4387666168 hasConceptScore W4387666168C2780962732 @default.
• W4387666168 hasConceptScore W4387666168C526805850 @default.
• W4387666168 hasConceptScore W4387666168C71924100 @default.
• W4387666168 hasConceptScore W4387666168C95190672 @default.
• W4387666168 hasIssue "10" @default.
• W4387666168 hasLocation W43876661681 @default.
• W4387666168 hasLocation W43876661682 @default.
• W4387666168 hasOpenAccess W4387666168 @default.
• W4387666168 hasPrimaryLocation W43876661681 @default.
• W4387666168 hasRelatedWork W1978017914 @default.
• W4387666168 hasRelatedWork W2037039278 @default.
• W4387666168 hasRelatedWork W2136984368 @default.
• W4387666168 hasRelatedWork W2138294834 @default.
• W4387666168 hasRelatedWork W2235788479 @default.
• W4387666168 hasRelatedWork W2297296679 @default.
• W4387666168 hasRelatedWork W2569965908 @default.
• W4387666168 hasRelatedWork W2809146871 @default.
• W4387666168 hasRelatedWork W3110357236 @default.
• W4387666168 hasRelatedWork W3140349894 @default.
• W4387666168 hasVolume "18" @default.
• W4387666168 isParatext "false" @default.
• W4387666168 isRetracted "false" @default.
• W4387666168 workType "article" @default.